核心观点 - Terns Pharmaceuticals公司宣布其候选药物TERN-701在治疗经治慢性髓系白血病患者的CARDINAL 1期临床试验中取得突破性疗效数据，24周时主要分子学反应率达到64%，在难治性患者群体中显示出前所未有的疗效潜力 [1][3] - 药物在所有评估剂量下均表现出令人鼓舞的安全性和耐受性特征，未观察到剂量限制性毒性，大多数治疗中出现的不良事件为低级别 [1][5] - 公司首席执行官认为这些数据验证了TERN-701有望成为改变CML治疗格局的最佳疗法，其疗效趋势比已获批或在研的其他CML疗法至少高出两倍 [3][4] 临床试验数据总结 - 截至2025年6月30日数据截止日，试验共入组55例患者，其中32例可进行疗效评估 [5] - 总体主要分子学反应率为75%，24例患者达到MMR [5] - 在难治性患者亚组中，24周累计MMR率表现强劲：对最后一种TKI缺乏疗效的患者为69%，既往接受过阿西米尼治疗的患者为60%，既往接受过阿西米尼/普纳替尼/研究性TKI治疗的患者为67% [5] - 入组患者为重度经治的难治性疾病：中位既往接受过3种TKI治疗，35%的患者接受过≥4种TKI，64%的患者因缺乏疗效而停用最后一种TKI [5] 安全性特征 - 87%的患者在数据截止时仍在接受治疗，停药原因包括疾病进展、不良事件和撤回同意/失访 [5] - 剂量递增期间未观察到剂量限制性毒性，未达到最大耐受剂量 [5] - 74%的治疗中出现的不良事件为低级别，最常见的是腹泻、头痛和恶心，均为1级或2级 [5] - 3级或以上不良事件均低于10%，最常见的是中性粒细胞减少症和血小板减少症 [5] 公司行动与后续计划 - 详细数据将于2025年12月8日在美血液学会年会上进行口头报告，报告标题为"CARDINAL: TERN-701用于经治CML患者的1期研究" [1][6] - 公司将于ASH报告后的美东时间12月8日下午4:30为投资者举行电话会议和网络直播，管理层将讨论CARDINAL试验数据及TERN-701的后续开发计划 [1][7] - 剂量递增部分已于2025年1月完成，剂量扩展部分于2025年4月启动，患者随机分配至两个剂量组，每组最多40例患者 [8] 药物与试验背景 - TERN-701是一种新型研究性变构BCR::ABL1抑制剂，目前正在CARDINAL试验中进行评估，这是一项全球多中心剂量递增和剂量扩展临床试验 [8] - Terns Pharmaceuticals是一家临床阶段肿瘤学公司，致力于通过重新认识已知生物学来提供高影响力药物 [9] - 公司认为TERN-701具有高度选择性、口服变构BCR-ABL抑制剂的特性，可能具备最佳疾病特征，有望显著改善现有CML治疗的疗效、安全性和便利性 [9]

Media ReleaseCOPENHAGEN, Denmark; November 3, 2025 More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of B-cell malignanciesNew data demonstrate potential of epcoritamab in first and second-line settings in follicular lymphoma (FL) and first-line in diffuse large B-cell lymphoma (DLBCL) Results from Phase 3 EPCORE FL-1 trial, evaluating epcoritama ...

Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202 in treating relapsed/refractory Acute Myeloid Leukemia (AML)Pharmacodynamic data further underscore clinical proof-of-mechanism for 'OR/NOT' Logic Gate, showing selective killing of leukemic blasts and leukemic stem cells (LSCs) while sparing healthy hematopoietic stem and progenitor cells (HSPCs)Updated clinical results continue to sh ...

LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of five abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held December 6-9, 2025, in Orlando, Florida. “Data to be presented at the upcoming ASH Annual Meeting continue to underscore the potential fo ...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that a Trial-in-Progress (TIP) poster highlighting the pivotal Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. ALPHA3 is ...

UAB “Atsinaujinančios energetikos investicijos” (the Company) publishes its factsheet, providing information about the Company’s investment portfolio, key events, business strategy, operating segments, and financial indicators as of 30 September 2025. Investment Company In August, the Bank of Lithuania approved AEI’s up to EUR 50,000,000 nominal value Unsecured Fixed Rate Note Programme. Solar projects In September 2025, AEI completed the divestment of its 2.6 MW solar project in Lithuania UAB “Saulės Energ ...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place December 6-9, 2025 in Orlando, FL. Details regarding the oral presentation are as follows: Session Name: 625. T Cell ...

LUOYANG, China, Nov. 03, 2025 (GLOBE NEWSWIRE) -- TRUNNANO, a leading global supplier of industrial ceramic materials, recently announced a significant breakthrough in the research, development, and manufacturing of its core product, reaction sintered silicon carbide (SiSiC). Through years of technological development and process optimization, the company has successfully overcome numerous technical challenges that have hindered the performance and reliability of this material, providing a more stable and c ...

Total of seven events in cities across Canada in 2025The Air Canada Foundation and Air Canada partnered with local autism organizations and airports as well as PAL Airlines and Jazz AviationLast event of the year took place yesterday in Vancouver MONTRÉAL, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Air Canada and the Air Canada Foundation are celebrating another successful year of their Autism Aviation Days events. These events aim to provide a supportive environment where children on the spectrum can familiarize th ...

2025年10月及1-10月零售额表现 - 2025年10月含税零售额达3470万欧元，同比增长4.9% [1] - 2025年1-10月含税零售额达3.005亿欧元，同比增长5.6% [1] - 分地区看，1-10月立陶宛零售额同比增长7.5%，拉脱维亚增长5.4%，爱沙尼亚下降1.3% [1] 门店网络与经营规模 - 公司目前运营171家门店，其中立陶宛103家、拉脱维亚44家、爱沙尼亚24家 [2] - 门店总营业面积达9.27万平方米，较一年前增加0.8% [2]